Please sign in to follow a disease.
Neurodevelopmental disorder
MONDO:0700092A behavioral and cognitive disorder with onset during the developmental period that involves impaired or aberrant development of intellectual, motor, or social functions.
952 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for rare hunger disorder: drug shows promise in Long-Term trial
Disease control TerminatedThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve qual…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Gene therapy trial for rare childhood epilepsy halted after just one patient
Disease control TerminatedThis trial tested a single dose of CAP-002 gene therapy in children aged 18 months to 8 years with STXBP1 encephalopathy, a rare genetic brain disorder causing seizures and developmental delays. The study aimed to check safety and whether it could reduce seizures and improve skil…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Seizure drug safety trial halted early for dravet and LGS patients
Disease control TerminatedThis study looked at the long-term safety of soticlestat when added to standard seizure medicines for people with Dravet syndrome or Lennox-Gastaut syndrome. It included 352 children and adults who had already been in earlier studies. The trial was terminated early, so results ar…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Promising seizure drug study halted early
Disease control TerminatedThis study looked at the long-term safety of the drug NBI-921352 for people with a rare genetic seizure disorder called SCN8A-DEE. It was an extension of an earlier study, and participants took the drug alongside their usual seizure medications. The study was stopped early and on…
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a repurposed drug tame seizures in adult dravet patients?
Disease control TerminatedThis study tested the drug fenfluramine (FINTEPLA) in adults with Dravet syndrome whose seizures were not controlled by other medications. The trial was open-label and added fenfluramine to existing treatments. It aimed to see if the drug could reduce monthly seizures by at least…
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug shows promise for Tough-to-Treat seizures in kids
Disease control TerminatedThis study looked at the long-term safety of soticlestat, an experimental drug, in children and adults with severe forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. Participants took soticlestat twice a day along with their usual seizure medicines. The study was…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Virtual coaching for toddlers with autism shows promise but trial cut short
Disease control TerminatedThis study tested a completely virtual early intervention program for toddlers with autism, using telehealth coaching to help parents embed learning into daily activities. Researchers planned to enroll 240 children from eight US regions, but the trial was terminated early with on…
Phase: NA • Sponsor: Florida State University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Epilepsy drug study for kids halted early: what we know
Disease control TerminatedThis study looked at the long-term safety of a drug called NBI-827104 in children with a rare epilepsy that causes seizures during sleep. The trial was stopped early and only enrolled 19 children, so the results are limited. The main goal was to see how many children had serious …
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising epilepsy drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called NBI-921352 in people aged 2 to 21 with a rare, severe form of epilepsy caused by a change in the SCN8A gene. The goal was to see if adding this drug to their current seizure medicines could reduce how often they had seizures. The tria…
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Dravet syndrome drug trial halted early: did lorcaserin help?
Disease control TerminatedThis study tested whether lorcaserin, when added to current medications, could reduce convulsive seizures in people with Dravet syndrome, a severe form of epilepsy. The trial planned to enroll about 22 participants aged 2 and older, but it was terminated early. The main goal was …
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief TerminatedThis phase 3 trial tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either ARD-101 or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a standard…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
CBDV study for Prader-Willi syndrome halted early
Symptom relief TerminatedThis study tested whether a cannabis-derived compound called CBDV could safely reduce irritability in children and young adults with Prader-Willi syndrome. Only 6 people enrolled before the study was stopped early. The goal was to see if CBDV helped with mood and behavior problem…
Phase: PHASE2 • Sponsor: Eric Hollander • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Autism social trial halted: memantine shows no promise
Symptom relief TerminatedThis study tested whether memantine, a medication for Alzheimer's, could improve social skills in youth aged 8-18 with autism or nonverbal learning disability. The trial was stopped early after enrolling only 25 participants. The main goal was to measure changes in social functio…
Phase: PHASE3 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Autism irritability drug trial ends early: what happened?
Symptom relief TerminatedThis study looked at the long-term safety of pimavanserin for treating irritability in children and teens (ages 5-17) with autism. It was an extension of an earlier 6-week study, lasting 52 weeks. The trial was terminated early, and results are not yet fully available.
Phase: PHASE2, PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
CBD study for baby seizures halted early
Symptom relief TerminatedThis study tested a cannabidiol (CBD) oral solution in children under 2 years old with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome who had uncontrolled seizures. The goal was to see if CBD is safe and can reduce seizures. However, the study was termina…
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
5-Minute wellness program for caregivers shows promise, study cut short
Symptom relief TerminatedThis study tested a program called 5Minutes4Myself, designed to help caregivers of autistic children (ages 8-21) manage stress and improve their well-being. Participants worked with a coach to create a personalized wellness plan and used a phone app with reminders and mindfulness…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Glutathione study for autism fizzles out early
Symptom relief TerminatedThis study aimed to see if taking glutathione by mouth is safe and practical for children and teens with autism. Researchers planned to enroll 24 participants but stopped early with only 6. The goal was to measure changes in behavior and social skills over 12 weeks.
Phase: PHASE4 • Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jun 26, 2026 18:02 UTC
-
Sibling power: could brothers and sisters be the key to autism therapy?
Symptom relief TerminatedThis study explored whether training typically developing siblings to teach reading and social skills can help children with autism. The approach used a simple teaching method called model-lead-test, where the sibling shows, practices, and gives feedback. Only 8 families took par…
Phase: NA • Sponsor: Arizona State University • Aim: Symptom relief
Last updated Jun 26, 2026 16:44 UTC
-
Brain and eye clues to emotion recognition in autism and psychosis
Knowledge-focused TerminatedThis study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…
Phase: NA • Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Brain scans reveal how autistic people process sensory overload
Knowledge-focused TerminatedThis study aimed to understand why people with autism often feel overwhelmed by sensory input like bright lights or loud noises. Researchers planned to use virtual reality and brain scans to see how the brain reacts to unpleasant visual stimuli. The study was terminated early and…
Phase: NA • Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists hunt for clues in rare genetic brain disorder
Knowledge-focused TerminatedThis study aimed to observe how MECP2 duplication syndrome progresses over time by measuring biological markers in spinal fluid and blood, and by tracking changes in development, behavior, and seizures. It enrolled 29 males aged 1 month to 65 years with a confirmed genetic diagno…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Zapping the brain to unravel OCD in kids
Knowledge-focused TerminatedThis study looked at how a gentle brain stimulation technique called tDCS affects thinking and behavior in children aged 10-17 with obsessive-compulsive disorder (OCD). The goal was to understand brain processes linked to OCD, not to treat the condition. Only 6 participants were …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Rare disease study aims to map MLIV's natural course
Knowledge-focused TerminatedThis study followed 7 people with Mucolipidosis Type IV (MLIV) to learn how the disease naturally progresses. Researchers used tests like neuropsychological exams, blood and urine tests, and brain MRIs to find better ways to measure the disease. The goal was to improve future cli…
Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Can an eHealth program help teachers support kids with ADHD, autism, and learning disabilities?
Knowledge-focused TerminatedThis study tested an online program called Teacher Help, designed to train teachers in evidence-based strategies for students with ADHD, autism spectrum disorder, or learning disabilities. Teachers worked through six online sessions with support from school psychologists. The goa…
Phase: NA • Sponsor: IWK Health Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC